SIDLEY

February 2, 2017



Pharmaceutical Industry Executives Meet with President Trump on January 31, 2017

On January 31, 2017, President Donald Trump met with six pharmaceutical industry executives from Amgen, Eli Lilly, Johnson & Johnson, Novartis, Merck, and Celgene to discuss drug pricing and approval matters. PhRMA CEO Stephen J. Ubl and House Energy and Commerce Committee Chairman Greg Walden (R-OR) also attended the meeting.

During this meeting, President Trump —

- reiterated his commitment to lowering the cost of drugs, particularly with respect to prices in the Medicaid and Medicare programs. He noted that prices can be lowered through increased competition and "bidding wars," but stopped short of calling for negotiated pricing, which he supported during the campaign.
- stated that his administration's trade policy will "prioritize the foreign countries that pay their fair share for U.S.-manufactured drugs." Trade policy, particularly with respect to intellectual property, is a significant issue for the pharmaceutical industry. He also indicated that he wants drug manufacturers to move their companies back to the United States.
- reported that he would reduce the regulatory burden on the pharmaceutical industry and take steps to speed the FDA drug approval process.
- noted that he would name the new FDA Commissioner soon.

If you have any questions regarding this Sidley Update, please contact the Sidley lawyer with whom you usually work or

Stephanie P. Hales
Partner
shales@sidley.com
+1 202 736 8349

Patricia Deloatche Senior Policy Advisor pdeloatche@sidley.com +1 202 736 8862 Dora Hughes, M.D., M.P.H. Senior Policy Advisor dhughes@sidley.com +1 202 736 8653 Laura R. Cohen
Policy Attorney
laura.cohen@sidley.com
+1 202 736 8127

Sidley Government Strategies Practice

Sidley's Government Strategies group works at the crossroads of law and policy, helping clients develop and implement strategies which protect and further their business interests. Multiple institutions influence the development of federal law and policy — including the Legislative, Executive and Judicial branches of government as well as the private and non-profit sectors. The professionals in our Government Strategies practice work with our clients to assist them in understanding and managing these multiple influences in a successful manner. Our group features a 28-year veteran of the U.S. House of Representatives who chaired the Energy and Commerce Committee's Subcommittee on Energy and Air Quality, a former Acting U.S. Attorney General, former general counsels for EPA, OMB and the Department of Agriculture, and former Counselors to the Secretary of the Department of Health and Human Services (HHS), among others who have filled high-profile posts. A number of our lawyers have had major roles in the drafting, enactment and regulatory implementation of landmark laws. This rare mix of leadership translates to an unusual level of value for our clients.

Sidley Healthcare Practice

Our Healthcare Practice represents participants in all facets of the healthcare industry, including pharmaceutical, biotech and device companies, DME suppliers, hospitals, skilled nursing facilities, physician-owned companies, professional associations and research institutions. Our lawyers combine a strong background in the complexities of healthcare financing and delivery, including coding, reimbursement, and coverage issues, privacy and security, trade regulation, and competition. We have extensive experience representing clients on enforcement and regulatory matters before federal and state enforcement agencies.

For more information and updates, please visit our Health Matters: Navigating ACA Reform website.

To receive Sidley Updates, please subscribe at www.sidley.com/subscribe.



$$\label{eq:boston} \begin{split} & \mathsf{BEIJING} \cdot \mathsf{BOSTON} \cdot \mathsf{BRUSSELS} \cdot \mathsf{CENTURY} \, \mathsf{CITY} \cdot \mathsf{CHICAGO} \cdot \mathsf{DALLAS} \cdot \mathsf{GENEVA} \cdot \mathsf{HONG} \, \mathsf{KONG} \cdot \mathsf{HOUSTON} \cdot \mathsf{LONDON} \\ & \mathsf{LOS} \, \mathsf{ANGELES} \cdot \mathsf{MUNICH} \cdot \mathsf{NEW} \, \mathsf{YORK} \cdot \mathsf{PALO} \, \mathsf{ALTO} \cdot \mathsf{SAN} \, \mathsf{FRANCISCO} \cdot \mathsf{SHANGHAI} \cdot \mathsf{SINGAPORE} \cdot \mathsf{SYDNEY} \cdot \mathsf{TOKYO} \cdot \\ & \mathsf{WASHINGTON}, \ \mathsf{D.C.} \end{split}$$

 $Sidley \ and \ Sidley \ Austin \ refer \ to \ Sidley \ Austin \ LLP \ and \ affiliated \ partnerships \ as \ explained \ at \ www.sidley.com/disclaimer.$

www.sidley.com